eb05
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04401475)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 4AGONIST
TLR4 agonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095366 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06701669 | Phase 2 | Jan 6, 2025 | Department of Health and Human Services, Edesa Biotech Inc., Genentech, InflaRx GmbH, PPD |
| NCT06703073 | Phase 2 | Dec 20, 2024 | Department of Health and Human Services, Edesa Biotech Inc., Genentech, InflaRx GmbH, PPD |
| NCT04401475 | Phase 2 | Jul 31, 2020 | Edesa Biotech Inc., JSS Medical Research Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Edesa Biotech Inc. | For profit | 3 | 1 | 1 | 2020 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2024 |
| Genentech | For profit | 2 | 0 | 1 | 2024 |
| InflaRx GmbH | For profit | 2 | 0 | 1 | 2024 |
| PPD | For profit | 2 | 2 | 1 | 2024 |
| JSS Medical Research Inc. | For profit | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1